Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05646381

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Conditions: Aortic Stenosis

Sex: All

Ages: 50 Years – 80 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 502

Sponsor: Novartis Pharmaceuticals

Location: Heart Center Research Llc Huntsville Alabama

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.

Eligibility Criteria

Inclusion Criteria: * Male and female ≥50 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05646381). StuddyBuddy aggregates publicly available trial information.